Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$14.53 -1.1%	$15.26	$12.83 ▼ $29.12	$205.98M	0.82	69,544 shs	49,519 shs
ISR Isoray		$0.37	$0.19 ▼ $0.45	$54.57M	1.48	290,697 shs	145,000 shs
LUNG Pulmonx	$4.83 -8.3%	$6.63	$4.15 ▼ $10.01	$194.39M	0.61	314,722 shs	328,098 shs
NYXH Nyxoah	$6.14 +2.5%	$8.13	$5.55 ▼ $12.21	$204.02M	1.55	67,364 shs	68,419 shs

20 Stocks to Sell Now

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	-1.09%	+2.98%	-3.33%	-15.91%	-43.88%
ISR Isoray	0.00%	0.00%	0.00%	0.00%	0.00%
LUNG Pulmonx	-8.35%	-3.21%	-28.23%	-15.11%	-36.53%
NYXH Nyxoah	+2.50%	+1.82%	-12.03%	-41.52%	-41.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIK Anika Therapeutics	4.0535 of 5 stars	3.5	3.0	0.0	3.6	2.9	1.7	0.6
ISR Isoray	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	3.1871 of 5 stars	3.4	4.0	0.0	0.0	3.5	2.5	0.6
NYXH Nyxoah	2.2789 of 5 stars	3.5	3.0	0.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	3.00	Buy	$21.67	49.12% Upside
ISR Isoray	0.00	N/A	N/A	N/A
LUNG Pulmonx	2.75	Moderate Buy	$12.75	163.98% Upside
NYXH Nyxoah	3.00	Buy	$14.50	136.16% Upside

Current Analyst Ratings Breakdown

Latest ISR, LUNG, ANIK, and NYXH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/17/2025	ANIK Anika Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/16/2025	ANIK Anika Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $15.00
3/14/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
3/13/2025	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $20.00
3/10/2025	LUNG Pulmonx	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
3/10/2025	LUNG Pulmonx	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight ➝ Equal Weight
3/10/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy
3/10/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$119.91M	1.72	$4.12 per share	3.53	$14.50 per share	1.00
ISR Isoray	$10.80M	0.00	N/A	N/A	$0.43 per share	0.00
LUNG Pulmonx	$83.79M	2.32	N/A	N/A	$3.09 per share	1.56
NYXH Nyxoah	$4.52M	46.26	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$82.67M	-$3.85	N/A	N/A	N/A	-59.40%	-2.22%	-1.75%	5/9/2025 (Estimated)
ISR Isoray	-$7.27M	-$0.07	N/A	N/A	N/A	-115.91%	-17.12%	-16.15%	N/A
LUNG Pulmonx	-$60.84M	-$1.44	N/A	N/A	N/A	-67.31%	-55.36%	-33.53%	5/7/2025 (Estimated)
NYXH Nyxoah	-$46.77M	-$1.95	N/A	N/A	N/A	-1,043.93%	-51.68%	-40.11%	5/13/2025 (Estimated)

Latest ISR, LUNG, ANIK, and NYXH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NYXH Nyxoah	-$0.49	N/A	N/A	N/A	$1.64 million	N/A
5/9/2025	Q1 2025	ANIK Anika Therapeutics	$0.09	N/A	N/A	N/A	$27.50 million	N/A
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	N/A
3/13/2025	Q4 2024	NYXH Nyxoah	-$0.46	-$0.49	-$0.03	-$0.49	$2.02 million	$1.35 million
3/12/2025	Q4 2024	ANIK Anika Therapeutics	-$0.01	-$0.14	-$0.13	-$1.50	$29.00 million	$30.60 million
2/19/2025	Q4 2024	LUNG Pulmonx	-$0.45	-$0.33	+$0.12	-$0.33	$22.29 million	$23.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
ISR Isoray	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	5.34	3.78
ISR Isoray	N/A	14.38	13.99
LUNG Pulmonx	0.40	7.70	6.77
NYXH Nyxoah	0.21	5.28	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
ISR Isoray	11.32%
LUNG Pulmonx	91.04%
NYXH Nyxoah	N/A

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	7.86%
ISR Isoray	2.42%
LUNG Pulmonx	6.80%
NYXH Nyxoah	17.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	300	14.18 million	13.50 million	Optionable
ISR Isoray	N/A	142.11 million	138.67 million	Not Optionable
LUNG Pulmonx	250	40.25 million	37.24 million	Optionable
NYXH Nyxoah	110	34.06 million	28.23 million	Not Optionable

ISR, LUNG, ANIK, and NYXH Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 30 at 12:15 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 29 at 11:35 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 28 at 6:09 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 25, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 25, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 24, 2025 | accessnewswire.com

Stifel Nicolaus Cuts Nyxoah (NASDAQ:NYXH) Price Target to $14.00

April 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 23, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 22, 2025 | prnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Shareholders to Reach Out

April 22, 2025 | accessnewswire.com

Nyxoah (NASDAQ:NYXH) Price Target Lowered to $14.00 at Stifel Nicolaus

April 22, 2025 | americanbankingnews.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Shareholders to Learn More About the Investigation

April 21, 2025 | accessnewswire.com

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

April 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 18, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Shareholders to Inquire about Securities Investigation

April 18, 2025 | accessnewswire.com

Short Interest in Nyxoah S.A. (NASDAQ:NYXH) Expands By 164.1%

April 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to Connect

April 17, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

April 16, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Stockholders to Inquire about Securities Investigation

April 16, 2025 | accessnewswire.com

Conditional Issuance of Shares

April 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AI Takes Over Search: Is Google's Dominance At Risk?
By Ryan Hasson | April 7, 2025
View AI Takes Over Search: Is Google's Dominance At Risk?
PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy
By Thomas Hughes | April 28, 2025
View PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy
3 Energy Stock Winners Even as Oil Prices Plunge
By Chris Markoch | April 11, 2025
View 3 Energy Stock Winners Even as Oil Prices Plunge
T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip
By Jea Yu | April 29, 2025
View T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip
Is Intuitive Surgical a Buy After Volatile Reaction to Earnings?
By Chris Markoch | April 25, 2025
View Is Intuitive Surgical a Buy After Volatile Reaction to Earnings?

ISR, LUNG, ANIK, and NYXH Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$14.53 -0.16 (-1.09%)

As of 04/30/2025 04:00 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Isoray NYSE:ISR

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Pulmonx NASDAQ:LUNG

$4.83 -0.44 (-8.35%)

As of 04/30/2025 04:00 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Nyxoah NASDAQ:NYXH

$6.14 +0.15 (+2.50%)

As of 04/30/2025 04:00 PM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time